JCR Pharmaceuticals Co., Ltd. (4552) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Kyowa Kirin Co., Ltd.

Suzuken Co., Ltd.

JCR Pharmaceuticals Co., Ltd.

Tsumura & Co.

Santen Pharmaceutical Co., Ltd.

Nippon Shinyaku Co., Ltd.

SAWAI GROUP HOLDINGS Co., Ltd.

Sumitomo Pharma Co., Ltd.

Hisamitsu Pharmaceutical Co., Inc.

Kobayashi Pharmaceutical Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

Why is JCR Pharmaceuticals Co., Ltd. ?

With a growth in Net Profit of 479.71%, the company declared Very Positive results in Mar 26

NET SALES(9M) At JPY 31,750 MM has Grown at 27.37%
PRE-TAX PROFIT(Q) At JPY 402 MM has Grown at 134.39%
NET PROFIT(Q) At JPY 400 MM has Grown at 155.16%

With ROCE of -6.76%, it has a risky valuation with a 1.40 Enterprise value to Capital Employed

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -13.42%, its profits have fallen by -249.8%

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -13.42% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to JCR Pharmaceuticals Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is JCR Pharmaceuticals Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

JCR Pharmaceuticals Co., Ltd.

-13.42%

-0.46

49.86%

Japan Nikkei 225

75.22%

2.67

28.15%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

7.52%

EBIT Growth (5y)

-202.13%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

0.45

Net Debt to Equity (avg)

0.53

Sales to Capital Employed (avg)

0.45

Tax Ratio

26.79%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.01%

ROCE (avg)

20.06%

ROE (avg)

13.01%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.72

EV to EBIT

-20.76

EV to EBITDA

-42.60

EV to Capital Employed

1.40

EV to Sales

3.11

PEG Ratio

Dividend Yield

ROCE (Latest)

-6.76%

ROE (Latest)

-6.79%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company

NET SALES(9M)

At JPY 31,750 MM has Grown at 27.37%

PRE-TAX PROFIT(Q)

At JPY 402 MM has Grown at 134.39%

NET PROFIT(Q)

At JPY 400 MM has Grown at 155.16%

RAW MATERIAL COST(Y)

Fallen by -46.2% (YoY

-10What is not working for the Company

INTEREST(HY)

At JPY 241 MM has Grown at 161.96%

DEBT-EQUITY RATIO (HY)

Highest at 85.26 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.44 times

Here's what is working for JCR Pharmaceuticals Co., Ltd.

Pre-Tax Profit

At JPY 402 MM has Grown at 134.39%

over average net sales of the previous four periods of JPY -1,169 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (JPY MM)

Net Profit

At JPY 400 MM has Grown at 155.16%

over average net sales of the previous four periods of JPY -725.12 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (JPY MM)

Net Sales

At JPY 31,750 MM has Grown at 27.37%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Raw Material Cost

Fallen by -46.2% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for JCR Pharmaceuticals Co., Ltd.

Interest

At JPY 241 MM has Grown at 161.96%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Debt-Equity Ratio

Highest at 85.26 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 0.44 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio